Byram Ozer, MD, PhD, is a board-certified neurologist and neuro-oncologist who specializes in the management and treatment of primary brain tumors and rare central nervous system (CNS) tumors.
Dr. Ozer is an associate professor in the Department of Hematology and Medical Oncology with a joint appointment in the Department of Neurology at Emory University School of Medicine. He serves as co-director of the Neuro-Oncology Program and director of Translational Research in Neuro-Oncology at Winship Cancer Institute of Emory University.
Before joining Emory, Dr. Ozer was an assistant research physician in the Neuro-Oncology Branch at the National Cancer Institute in Bethesda, Maryland, where he was a member of the NCI-CONNECT program.
Dr. Ozer earned his medical degree and PhD from the University of Wisconsin in Madison. He completed his internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, followed by a neurology residency and neuro-oncology fellowship at the University of California, Los Angeles.
Titles & Roles
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Associate Professor, Department of Neurology
Emory University School of Medicine
Co-Director, Neuro-Oncology Program
Winship Cancer Institute of Emory University
Director, Translational Research in Neuro-Oncology
Winship Cancer Institute of Emory University
Education & Training
Education
Fellowship, Neuro-Oncology, 2018
UCLA Medical Center
Residency, Neurology, 2015
UCLA Medical Center
Internship, Internal Medicine, 2012
Good Samaritan Hospital
Medical Education, MD, 2011
University of Wisconsin School of Medicine and Public Health
Board Certifications
Neurology
American Board of Psychiatry and Neurology, 2015
Research
As a physician-scientist and molecular biologist, Dr. Ozer’s translational research focuses on investigating tumor drivers and mechanisms of sensitivity in DNA repair, metabolic and immunological processes. His goal is to develop tailored mono and combination therapies. His clinical trial work centers on therapies for rare CNS tumors, with a special emphasis on malignant and treatment-refractory meningiomas.
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
